Sherr CJ. Cancer cell cycles. Science (New York, NY). 1996;274(5293):1672–7.
Ho A, Dowdy SF. Regulation of G(1) cell-cycle progression by oncogenes and tumor suppressor genes. Curr Opin Genet Dev. 2002;12(1):47–52.
CAS PubMed Article Google Scholar
Sachdeva UM, O’Brien JM. Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma. J Clin Investig. 2012;122(2):425–34.
CAS PubMed PubMed Central Article Google Scholar
Chauveinc L, Mosseri V, Quintana E, Desjardins L, Schlienger P, Doz F, et al. Osteosarcoma following retinoblastoma: age at onset and latency period. Ophthalmic Genet. 2001;22(2):77–88.
CAS PubMed Article Google Scholar
Dyson NJ. RB1: a prototype tumor suppressor and an enigma. Gene Dev. 2016;30(13):1492–502.
CAS PubMed PubMed Central Article Google Scholar
Lee JO, Russo AA, Pavletich NP. Structure of the retinoblastoma tumour-suppressor pocket domain bound to a peptide from HPV E7. Nature. 1998;391(6670):859–65.
CAS PubMed Article Google Scholar
Hassler M, Singh S, Yue WW, Luczynski M, Lakbir R, Sanchez-Sanchez F, et al. Crystal structure of the retinoblastoma protein N domain provides insight into tumor suppression, ligand interaction, and holoprotein architecture. Mol Cell. 2007;28(3):371–85.
CAS PubMed PubMed Central Article Google Scholar
Lee C, Chang JH, Lee HS, Cho Y. Structural basis for the recognition of the E2F transactivation domain by the retinoblastoma tumor suppressor. Gene Dev. 2002;16(24):3199–212.
CAS PubMed PubMed Central Article Google Scholar
Xiao B, Spencer J, Clements A, Ali-Khan N, Mittnacht S, Broceño C, et al. Crystal structure of the retinoblastoma tumor suppressor protein bound to E2F and the molecular basis of its regulation. Proc Natl Acad Sci USA. 2003;100(5):2363–8.
CAS PubMed PubMed Central Article Google Scholar
Rubin SM, Gall AL, Zheng N, Pavletich NP. Structure of the Rb C-terminal domain bound to E2F1-DP1: a mechanism for phosphorylation-induced E2F release. Cell. 2005;123(6):1093–106.
CAS PubMed Article Google Scholar
Kim HY, Ahn BY, Cho Y. Structural basis for the inactivation of retinoblastoma tumor suppressor by SV40 large T antigen. EMBO J. 2001;20(1–2):295–304.
CAS PubMed PubMed Central Article Google Scholar
Classon M, Harlow E. The retinoblastoma tumour suppressor in development and cancer. Nat Rev Cancer. 2002;2(12):910–7.
CAS PubMed Article Google Scholar
Dyson N. The regulation of E2F by pRB-family proteins. Gene Dev. 1998;12(15):2245–62.
CAS PubMed Article Google Scholar
Giacinti C, Giordano A. RB and cell cycle progression. Oncogene. 2006;25(38):5220–7.
CAS PubMed Article Google Scholar
Sherr CJ, McCormick F. The RB and p53 pathways in cancer. Cancer Cell. 2002;2(2):103–12.
CAS PubMed Article Google Scholar
Wikenheiser-Brokamp KA. Retinoblastoma regulatory pathway in lung cancer. Curr Mol Med. 2006;6(7):783–93.
Burkhart DL, Sage J. Cellular mechanisms of tumour suppression by the retinoblastoma gene. Nat Rev Cancer. 2008;8(9):671–82.
CAS PubMed PubMed Central Article Google Scholar
Venne AS, Kollipara L, Zahedi RP. The next level of complexity: crosstalk of posttranslational modifications. Proteomics. 2014;14(4–5):513–24.
CAS PubMed Article Google Scholar
Hitosugi T, Chen J. Post-translational modifications and the Warburg effect. Oncogene. 2014;33(34):4279–85.
CAS PubMed Article Google Scholar
Macdonald JI, Dick FA. Posttranslational modifications of the retinoblastoma tumor suppressor protein as determinants of function. Genes Cancer. 2012;3(11–12):619–33.
CAS PubMed PubMed Central Article Google Scholar
Meng F, Qian J, Yue H, Li X, Xue K. SUMOylation of Rb enhances its binding with CDK2 and phosphorylation at early G1 phase. Cell Cycle. 2016;15(13):1724–32.
CAS PubMed PubMed Central Article Google Scholar
Chan HM, Krstic-Demonacos M, Smith L, Demonacos C, La Thangue NB. Acetylation control of the retinoblastoma tumour-suppressor protein. Nat Cell Biol. 2001;3(7):667–74.
CAS PubMed Article Google Scholar
Cho HS, Hayami S, Toyokawa G, Maejima K, Yamane Y, Suzuki T, et al. RB1 methylation by SMYD2 enhances cell cycle progression through an increase of RB1 phosphorylation. Neoplasia. 2012;14(6):476–86.
CAS PubMed PubMed Central Article Google Scholar
Uchida C, Miwa S, Kitagawa K, Hattori T, Isobe T, Otani S, et al. Enhanced Mdm2 activity inhibits pRB function via ubiquitin-dependent degradation. EMBO J. 2005;24(1):160–9.
CAS PubMed Article Google Scholar
Knight JS, Sharma N, Robertson ES. Epstein–Barr virus latent antigen 3C can mediate the degradation of the retinoblastoma protein through an SCF cellular ubiquitin ligase. Proc Natl Acad Sci USA. 2005;102(51):18562–6.
CAS PubMed PubMed Central Article Google Scholar
Damgaard RB. The ubiquitin system: from cell signalling to disease biology and new therapeutic opportunities. Cell Death Differ. 2021;28(2):423–6.
PubMed PubMed Central Article Google Scholar
Sewduth RN, Baietti MF, Sablina AA. Cracking the monoubiquitin code of genetic diseases. Int J Mol Sci. 2020;21(9):3036.
CAS PubMed Central Article Google Scholar
Akutsu M, Dikic I, Bremm A. Ubiquitin chain diversity at a glance. J Cell Sci. 2016;129(5):875–80.
Baur R, Rape M. Getting close: insight into the structure and function of K11/K48-branched ubiquitin chains. Structure. 2020;28(1):1–3.
CAS PubMed Article Google Scholar
Yao TT, Ndoja A. Regulation of gene expression by the ubiquitin-proteasome system. Semin Cell Dev Biol. 2012;23(5):523–9.
CAS PubMed PubMed Central Article Google Scholar
Kang J, Chung KC. The F-box protein FBXO7 positively regulates bone morphogenetic protein-mediated signaling through Lys-63-specific ubiquitination of neurotrophin receptor-interacting MAGE (NRAGE). Cell Mol Life Sci. 2015;72(1):181–95.
CAS PubMed Article Google Scholar
Clague MJ, Heride C, Urbe S. The demographics of the ubiquitin system. Trends Cell Biol. 2015;25(7):417–26.
CAS PubMed Article Google Scholar
Zheng N, Shabek N. Ubiquitin ligases: structure, function, and regulation. Annu Rev Biochem. 2017;86:129–57.
CAS PubMed Article Google Scholar
Antao AM, Tyagi A, Kim KS, Ramakrishna S. Advances in deubiquitinating enzyme inhibition and applications in cancer therapeutics. Cancers. 2020;12(6):1579.
CAS PubMed Central Article Google Scholar
Hu Q, Ye Y, Chan LC, Li Y, Liang K, Lin A, et al. Oncogenic lncRNA downregulates cancer cell antigen presentation and intrinsic tumor suppression. Nat Immunol. 2019;20(7):835–51.
CAS PubMed PubMed Central Article Google Scholar
Khanna R, Krishnamoorthy V, Parnaik VK. E3 ubiquitin ligase RNF123 targets lamin B1 and lamin-binding proteins. FEBS J. 2018;285(12):2243–62.
CAS PubMed Article Google Scholar
Wang Y, Zheng Z, Zhang J, Wang Y, Kong R, Liu J, et al. A novel retinoblastoma protein (RB) E3 ubiquitin ligase (NRBE3) promotes RB degradation and is transcriptionally regulated by E2F1 transcription factor. J Biol Chem. 2015;290(47):28200–13.
CAS PubMed PubMed Central Article Google Scholar
Liu HJ, Wang JN, Liu Y, Hu LL, Zhang CF, Xing BC, et al. Human U3 protein14a is a novel type ubiquitin ligase that binds RB and promotes RB degradation depending on a leucine-rich region. Bba-Mol Cell Res. 2018;1865(11):1611–20.
留言 (0)